At a glance

Most Recent Events

31 May 2017
According to an MEI Pharma media release, an independent Safety Review Committee has completed its pre-specified review of the first cohort of six evaluable patients and declared a minimum biologically effective dose (mBED) for ME-401 at the starting dose of 60 mg and recommended escalation to a 120 mg dose cohort. Full data will be submitted for presentation at an upcoming scientific meeting.

04 May 2017
According to a MEI Pharma media release, interim safety and efficacy data from the first cohort of the study are expected in June.

08 Nov 2016
Status changed from not yet recruiting to recruiting.

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login
with a username/password associated to an account with a valid subscription